Soleus Capital Master Fund, L.P. 13D and 13G filings for ESSA Pharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-21 4:30 pm Purchase | 2025-07-17 | 13D | ESSA Pharma Inc. EPIX | Soleus Capital Master Fund, L.P. | 4,362,026 9.800% | 2,100,000 (+92.84%) | Filing |
| 2025-04-23 9:45 pm Unchanged | 2025-04-23 | 13D | ESSA Pharma Inc. EPIX | Soleus Capital Master Fund, L.P. | 2,262,026 5.100% | 0 (Unchanged) | Filing |
| 2025-04-15 4:46 pm Purchase | 2025-04-15 | 13D | ESSA Pharma Inc. EPIX | Soleus Capital Master Fund, L.P. | 2,262,026 5.100% | 2,262,026 (New Position) | Filing |